LBRX — LB PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1691082 ·
Last close
$40.30
Market Cap
$1.30B
52W High
$50.16
52W Low
$15.19
ADV30
412,520
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -62,498,000 -59,066,000 453,370,000 215,075,000 35,730,000
Jun 2026 0 — -53,915,000 -51,603,000 361,692,000 283,111,000 29,345,000
Mar 2026 0 — -22,104,000 -19,054,000 393,482,000 320,676,000 14,789,000
Dec 2025 0 — -13,870,000 -11,472,000 312,934,000 250,173,000 11,624,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-82,395,000
Investing CF
$-44,819,000
Financing CF
$396,374,000
CapEx
$-456,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.44
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-200,185,000
Inventory
—
Receivables
—
ST Investments
$44,679,000
EBIT TTM
$-95,135,000
Pretax Income TTM
$-85,684,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -30,404,000 -25,205,000 312,934,000 11,624,000 301,310,000 -35,208,000
Dec 2024 0 -64,830,000 -63,102,000 33,534,000 128,088,000 -94,554,000 -53,052,000
Dec 2023 0 -11,376,000 -6,275,000 45,657,000 80,130,000 -34,473,000 -12,094,000
Dec 2022 0 -2,809,000 -14,348,000 21,492,000 50,304,000 -28,812,000 -2,728,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$361,692,000
Forward EPS
$-5.74

Peers — same industry

TickerNameMarket CapLastDaily %
GPCR Structure Therapeutics Inc. $1.30B $18.17 —
INVA Innoviva, Inc. $1.30B $18.30 —
MNKD MANNKIND CORP $1.31B $4.07 —
OCUL OCULAR THERAPEUTIX, INC $1.32B $6.02 —
MLYS Mineralys Therapeutics, Inc. $1.28B $14.48 —

News headlines (Yahoo Finance, 1h cache)

LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
2026-11-05 22:28 · Yahoo
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 21:05 · Yahoo
Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data
2026-10-28 22:40 · Yahoo
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
2026-10-28 01:04 · Yahoo
LB Pharmaceuticals to Participate in Upcoming Investor Events
2026-10-15 20:05 · Yahoo
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
2026-10-10 12:00 · Yahoo
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-10-09 20:42 · Yahoo
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
2026-10-06 12:00 · Yahoo
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
2026-09-09 12:00 · Yahoo
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
2026-09-04 10:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.